Grand Pharmaceutical's needle-free epinephrine product, Auvi-Q®, launches in China

On April 18, the 'Severe Allergic Reaction Diagnosis and Treatment and Emergency Standards Forum and Auvi-Q® National Launch Conference', jointly initiated by authoritative experts from various fields such as allergy departments, pediatrics, emergency medicine, and public health, was successfully held. At the conference,$GRAND PHARMA (00512.HK)$ Beijing Grand Jihe Pharmaceutical Co., Ltd., under Grand Pharmaceutical, in collaboration with You'er Pharmaceutical Trading (Beijing) Co., Ltd., under Beijing Summit Biomedical Co., Ltd., announced that the world’s first needle-free epinephrine nasal spray—Auvi-Q®—has officially entered the Chinese market.

Severe allergic reactions develop rapidly and progress quickly, triggering anaphylactic shock or even death within minutes. However, the defense system against severe allergic reactions in our country has long faced three major challenges: 'difficult identification, delayed medication, and lack of resources outside hospitals.' Data shows that the overall usage rate of epinephrine for severe allergic reactions is only 25%, and even in life-threatening severe cases, only 34% of patients received epinephrine. Seventy percent of deaths are directly related to the untimely use of epinephrine. Current mainstream clinical guidelines or expert consensus both domestically and internationally clearly state that epinephrine is the first-line emergency treatment for severe allergic reactions.

Launch Ceremony of Yu Min Su

Yu Min Su is the first non-injectable epinephrine nasal spray product approved by the US Food and Drug Administration (FDA) for Type I allergic reactions (including severe allergic reactions), utilizing an innovative nasal spray delivery method. This allows the patient or others to administer the drug immediately in case of an emergency allergic reaction. The product boasts a shelf life of up to 30 months, significantly reducing waste caused by expired medications and easing the financial and medication burden on patients. Results from pivotal clinical studies show that participants treated with Yu Min Su or approved epinephrine injection products had comparable blood concentrations of epinephrine, and it has been proven that Yu Min Su can act quickly and alleviate symptoms within a short period for patients with allergic reactions. [1]

Continuously deepening innovation pipeline layout to consolidate advantages in cardiovascular emergency care

The cardiovascular emergency care sector is one of the key areas of focus in the pharmaceutical technology field of our group, balancing both emergency rescue and chronic disease management. In terms of emergency care, our group has been designated as a 'National Essential Medicines Production Base,' a 'National Strategic Reserve Emergency Medicine Production Enterprise,' and a 'National Small Volume Drug (Shortage Drug) Centralized Production Base Construction Unit.' We have over 30 varieties of drugs, 14 of which are included in China's National Emergency Rescue Medication List, and 16 are listed in the Shortage Medication List. Our product pipeline ranks among the top in the industry, covering three major emergency scenarios: in-hospital emergency care, pre-hospital emergency care, and community emergency care, continuously providing domestic cardiovascular emergency patients with multi-scenario, multiple-choice, safe, and effective product combinations. In the direction of chronic disease management, core products such as Neng Qi Lang, Li Mei Tong Eplerenone Tablets, He Xin Shuang/He Bei Shuang, continue to lead niche markets. Currently, through a combination of independent innovation R&D and breakthroughs in high-difficulty generic technologies, the cardiovascular emergency care sector continues to expand and develop products urgently needed in clinical practice for cardiovascular emergency care and chronic disease treatment.

The Board of Directors of Grand Pharmaceutical Group Limited stated: 'Our group has always placed great emphasis on the research and development of innovative products and advanced technologies, with patient needs at the core and technological innovation as the driving force. In response to unmet clinical needs, we will increase investment in global innovative products and advanced technologies, enriching and improving our product pipeline and industrial layout. By adopting a 'global operational layout, dual-circulation business development' strategy, we aim to create a new pattern of dual-circulation linkage between domestic and international operations that mutually reinforce each other, fully leveraging our group's industrial advantages and R&D capabilities to quickly bring innovative products to market, providing more advanced and diverse treatment options for patients worldwide.'

[1] According to clinical study results of Yu Min Su;

[2] If you wish to learn more about disease-related knowledge, please consult healthcare professionals.

Forward-Looking Statements:

This press release aims to share updates and developments related to the group's business operations and is intended for healthcare professionals only, not for advertising purposes. The information provided in this press release is for reference only and should not be used as a basis for diagnosis or treatment. If you experience any health issues, please seek medical attention promptly. The group does not recommend any specific drugs or indications.

This press release may contain certain forward-looking statements. These statements inherently involve significant risks and uncertainties. When using terms such as 'expect,' 'believe,' 'predict,' 'anticipate,' 'intend,' or similar expressions related to the group, they constitute forward-looking statements. The group is under no obligation to continuously update these predictive statements.

These forward-looking statements are based on the current views, assumptions, expectations, estimates, forecasts, and understanding of future events by the group’s management at the time of making such statements. They are not guarantees of future performance and are subject to risks, uncertainties, and other factors, some of which are beyond the group’s control and difficult to predict. Therefore, actual results may differ significantly from the information contained in forward-looking statements due to changes and developments in our business, competitive environment, political, economic, legal, and social conditions.

The Group, its directors, and employees shall not be obligated to (1) correct or update any forward-looking statements contained on this website; nor shall they bear (2) any liability arising from the failure or inaccuracy of any forward-looking statements.

9017 Views